Health Canada greenlights Novartis’ Kisqali for early-stage breast cancer treatment
The approval is for adults with early-stage breast cancer characterised by hormone receptor positivity and human epidermal growth factor receptor 2 negativity, who are at a high risk of recurrence.
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry